1000L Low Temperature Refrigerated BOD Incubator NovaIncu BOD-1000A(Programmable)

Features:

• Designed with a fully stainless steel interior for easy cleaning and corrosion resistance.
• External powder-coated steel housing and large safety glass window ensure durability and visibility.
• Dual-door structure provides an effective thermal barrier.
• High-performance compressor delivers reliable cooling with protective features and low fluctuation.
• Uniform 3D heating is perfect for sensitive biological and material tests.
• Integrated power outlet (110V/220V) makes it ready for BOD and other standard tests.
• Advanced controller with a high-speed chip allows for precise and complex temperature profiles.
• Supports extended automated testing with its 99-hour programmable timer.
• An extensive alarm system ensures process integrity and equipment safety.
• Optional independent over-temperature protection and UV lamp add critical functionality for specialized labs.

Specifications

*Notes:

MD80B/150B/250B/360B/450B/750B have10-segment temperature control program to realize temperature curve program running. The inflow and outflow air speed is also adjustable.

Introduction about incubator

The development of biosimilars—biologic medicines highly similar to an existing approved reference product—requires rigorous analytical comparison. Incubators support several key assays in this characterization.

Cell-based potency assays are central. The biosimilar and reference product are applied to sensitive cell lines (e.g., those proliferating in response to a growth factor) cultured in CO2 incubators. The biological activity (potency) is measured and must be equivalent. Forced degradation studies also use incubators. Samples of both products are stressed under controlled conditions—elevated temperature (e.g., 25°C, 40°C) in stability chambers or incubators—and then analyzed for changes in aggregates, fragments, or charge variants compared to the reference.

Furthermore, incubators are used in assays to detect host cell proteins (HCPs) or in ELISA-based immunogenicity risk assessments. The precision and documentation capabilities of modern incubators are vital here. Any difference in incubation conditions could lead to variable cell responses or degradation profiles, potentially misinterpreted as a product difference. Therefore, the incubator contributes to the “totality of evidence" required by regulators to demonstrate that a biosimilar is as safe and effective as its originator, ensuring patient access to more affordable biologic therapies.